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Protein exportNumerous therapeutic proteins are expressed in Escherichia coli and targeted to the periplasm in order to facili-
tate puriﬁcation and enable disulﬁde bond formation. Export is normally achieved by the Sec pathway, which
transports proteins through the plasma membrane in a reduced, unfolded state. The Tat pathway is a promising
alternativemeans of export, because it preferentially exports correctly foldedproteins; however, the reducing cy-
toplasm of standard strains has been predicted to preclude export by Tat of proteins that contain disulﬁde bonds
in the native state because, in the reduced state, they are sensed asmisfolded and rejected. Here,wehave tested a
series of disulﬁde-bond containing biopharmaceuticals for export by the Tat pathway in CyDisCo strains that do
enable disulﬁde bond formation in the cytoplasm.We show that interferonα2b, human growth hormone (hGH)
and two antibody fragments are exported with high efﬁciency; surprisingly, however, they are efﬁciently
exported even in the absence of cytoplasmic disulﬁde formation. The exported proteins acquire disulﬁde
bonds in the periplasm, indicating that the normal disulﬁde oxidation machinery is able to act on the proteins.
Tat-dependent export of hGH proceeds even when the disulﬁde bonds are removed by substitution of the Cys
residues involved, suggesting that these substrates adopt tertiary structures that are accepted as fully-folded
by the Tat machinery.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Escherichia coli is a popular host for the production of recombinant
proteins, underpinning the production of over a third of currently-
licensed therapeutic proteins [28]. There are several strategies for pro-
duction of these biopharmaceuticals in E. coli, including expression of
soluble proteins in the cytoplasm, expression as insoluble inclusion
bodies or export to the periplasm followed by selective rupturing of
the outer membrane to release the protein [22]. The latter is a favoured
approach formany protein products, because it offersmajor advantages
in downstream processing, including a reduction in the release of con-
taminant proteins and proteases, a lack of DNA release and less debris
micronisation, hence better clariﬁcation performance (reviewed in [2,
11]). In addition, the periplasm is an oxidising environment, which ison).essential for the production of disulﬁde bond-containing proteins. In
wild type E. coli host strains, these cannot form in the cytoplasm.
Export of biopharmaceuticals to the periplasm is normally achieved
by attachment of an N-terminal ‘Sec’-type signal peptide which directs
export via the general secretory (Sec) pathway (reviewed in [9]). This
system transports protein substrates through a membrane-bound
translocase in an unfolded form, after which the protein folds in the
periplasm and any disulﬁde bonds are formed at this point. However,
a high proportion of heterologous proteins are Sec-incompatible be-
cause they fold too rapidly, or too tightly, for the Sec pathway to handle
effectively. In this context, the twin-arginine translocation (Tat) system
offers a potentially important alternative to the Sec pathway. It operates
in parallel with the Sec pathway in most bacteria but uses a completely
different translocation mechanism. As with Sec substrates, Tat sub-
strates are synthesised with N-terminal signal peptides, but these
contain speciﬁc determinants including the presence of a highly con-
served twin-argininemotif. The Tat pathway has two unique properties
that have major implications for its exploitation.
Table 1
Strains and constructs used in this study.
Strain/plasmid Description Source/reference
DH5α F_ _80lacZ_M15_(lacZYA-argF) U169
deoR recA1 endA1 hsdR17 (RK_,mk_)
gal-phoA supE44 thi-1 gyrA96 relA1
Invitrogen,
Carlsbad, CA, USA
W3110 F- mcrA mcrB IN(rrnD-rrnE)1 lambda- ATCC, Manassas,
VA, USA
MC4100, AraR AraR, FaraD139DlacU169 rpsL150 relA1
ﬂB5301 deoC1 ptsF25 rbsR
Bolhuis et al. [4]
ΔTatABCDE,
AraR
Like MC4100 AraR; ΔtatABCDE Wexler et al. [29],
Bolhuis et al. [4]
K12, ΔdsbB Δ(araD-araB)567 ΔLacZ4787(::rrnB-3)
λ- dsbB774::kan rph-1 Δ(rhaD-rhaB)
568 hsdR514
Baba et al. [1]
BL21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm]
ΔhsdS λ DE3 = λ sBamHIo ΔEcoRI-B
int::(lacI::PlacUV5::T7 gene1) i21 Δnin5
Miroux and Walker
[18]
pYU49 pET23 based vector with pTac promoter
expressing TorAsp IL-1β scFv,
codon-optimised Erv1p and mature
codon-optimised hPDI
Matos et al. [16]
pHAK1 As above with mature hGH-6His
replacing IL-1β scFv
This study
pHAK2 As above with mature α2b IFN-6His
replacing IL-1β scFv
This study
pHAK7 As above with β-galactosidase
scFv-6His replacing IL-1β scFv
This study,
Martineau et al.
[13]
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therefore has real potential for the export of proteinswith folding prop-
erties that preclude Sec-dependent export. An example is green ﬂuores-
cent protein (GFP), a tightly-folding protein that cannot normally be
exported by Sec, but which is very efﬁciently exported by Tat [27].
Moreover, the Tat pathway can support levels of protein export that
are comparable to those obtained in Sec-dependent industrial produc-
tion systems; fed-batch fermentation studies showed that periplasmic
GFP levels exceeded 1 g protein per litre culture [16].
A second Tat trait is also highly relevant for biotechnological exploi-
tation purposes: not only is Tat capable of exporting fully folded pro-
teins, there is widespread evidence that it preferentially exports
correctly folded proteins— even heterologous proteins. Indeed, studies
onmutated versions of several substrates have shown an all-or-nothing
effect, in that misfolded proteins are essentially 100% rejected (for ex-
ample [10,17]; reviewed in [26]). The underlying quality control mech-
anism is poorly understood, but there is evidence that the proofreading
ability of the Tat pathway can involve at least two elements: co-factor
insertion and substrate assembly mediated by protein chaperones
such as DmsD, HybE, NapD and TorD [6,20] or direct interaction with
the translocase itself (for review see [21]). These reports showed that
misfolded proteins, with even minor changes in structure, could lead
to reduced or blocked translocation, although some exceptions have
been noted; for example Richter et al. [25] showed that small, unstruc-
tured hydrophilic proteins (b30 kDa) could be transported. In general,
this proofreading ability is poorly understood, but however it works,
the trait is potentially important for biotechnological exploitation of
Tat, because it implies that exported products should have high speciﬁc
activities and minimal heterogeneity.
While this trait has interesting implications for the use of Tat in pro-
duction platforms, there is evidence that it may cause problems for the
export of disulﬁde-bond requiring proteins. Several proteins which
contain disulﬁde bonds in the native state could not be exported by
Tat, because they were found to be misfolded, and hence completely
Tat-incompatible, in the absence of cytoplasmic disulﬁde formation [5,
16]. However, some proteins were exported in an E. colimutant strain,
Δgor/ΔtrxB, that allows formation of the disulﬁde bonds in the cyto-
plasm [5]. Similar results were obtained by our group when we
expressed disulﬁde-requiring proteins in ‘CyDisCo’ (Cytoplasmic
Disulﬁde formation in E. coli) strains that promote efﬁcient formation
of disulﬁde bonds in the cytoplasm [16]. The Tat pathway thus clearly
identiﬁed these constructs asmisfolded inwild type strains and rejected
them. Hence, Tat-dependent export required prior oxidative folding.
CyDisCo strains express a yeast mitochondrial thiol oxidase, Erv1p
and human protein disulﬁde isomerase (PDI) which confer the ability
to catalyse cytoplasmic disulﬁde bond formation and isomerization
and these factors were shown to enable the Tat-dependent export of
two disulﬁde-requiring model proteins, namely PhoA and AppA. These
results suggested that it has promise for the export of disulﬁde-
requiring biopharmaceuticals, and in this study we have tested a series
of such proteins for export by the Tat pathway. We show that the pro-
teins are all efﬁciently exported in Erv1p/PDI-expressing cells; a major
surprise, however, is the ﬁnding that export is equally efﬁcient in wild
type cells. In the absence of Erv1p and PDI, the proteins are shown to ac-
quire disulﬁde bonds in the periplasm, andwe speculate that this subset
of proteins are exported by Tat in the reduced form because they adopt
a near-native structure that enables them to avoid rejection by the Tat
pathway's proofreading system.pHAK12 As above with VH domain-6His
replacing IL-1β scFv
This study
pHAK14 As pHAK1 but without Erv1p and PDI This study
pHAK15 As pHAK2 but without Erv1p and PDI This study
pHAK17 As pHAK7 but without Erv1p and PDI This study
pHAK23 As pHAK12 but without Erv1p and PDI This study
pKWK1 As pHAK1 with C53S mutation This study
pKWK2 As pHAK1 with C189S mutation This study
pKWK3 As pHAK1 with C53S C189S mutation This study2. Materials and methods
2.1. Materials
All chemicals, unless speciﬁed otherwise, were obtained from Sigma
Chemical Co. Ltd. (Poole, Dorset, UK) and were of analytical grade.2.2. Plasmids & bacterial strains
All constructs were ampliﬁed using Phusion high ﬁdelity DNA poly-
merase (New England Biolabs) to include a 5′ NdeI site and a 3′ BamHI
site immediately after a 6-His tag. The product was then digested with
NdeI and BamHI (New England Biolabs) and inserted into pYU49
which had been cut similarly [16].
All plasmid puriﬁcation was performed using the QIAprep spin
miniprep kit (Qiagen) and all puriﬁcation from agarose gels was
performed using the gel extraction kit (Qiagen), both according to the
manufacturer's instructions. All plasmids generated were fully se-
quenced (see Table 1 for plasmid names and details). The sequence of
the VH domain construct is shown in the Supplementary data section.
2.3. Growth conditions
Following transformation, a single colony was used to inoculate
10 mL of LB media containing 100 μg mL−1 ampicillin and grown over-
night at 37 °C, 200 rpm. Using the overnight culture, 50 mL of LB in i L
ﬂasks containing appropriate antibiotics was inoculated to OD600 =
0.05 and grown to approximately OD600 = 0.5 at 37 °C, 200 rpm. At
OD600 = 0.5, cells were induced with 1 mM IPTG and left for 3 h at
25 °C or 30 °C (see main text), 200 rpm. After this time an amount
equivalent to 1 mL of OD600 = 10 was collected by centrifugation
(3000 rpm, 10 min). The periplasmic fraction (P) was prepared by the
EDTA/lysozyme/cold osmoshock procedure [22,24]. After removal of
the periplasm supernatant the spheroplast pellet was then washed
with buffer containing 50 mM Tris–Acetate (pH 8.2), 250 mM sucrose
and 10 mMMgSO4 and centrifuged for 5 min at 14,000 rpm, 4 °C. The
resulting pellet was then resuspended in 50 mM Tris–Acetate, 2.5 mM
EDTA (pH 8.2) and sonicated on ice for 4–6 × 10 s, 8 μm amplitude
with 10 s between sonication (Soniprep 150plus, Sanyo Gallenkamp,
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70,000 rpm, 4 °C to collect the insoluble fraction. The supernatant was
removed as the cytoplasmic fraction (C) and the pellet resuspended in
50 mM Tris–Acetate, 2.5 mM EDTA (pH 8.2.) to give the membrane/in-
soluble fraction (M). All cell fractions were stored frozen in aliquots for
further experiments as repeated freeze-thawing can inﬂuence the re-
sults obtained in a protein-dependent manner.
2.4. Detection of proteins by immunoblotting; protein puriﬁcation
After SDS-PAGE and transfer, PVDFmembranes to be immunoblotted
with C-terminal His antibodies were blocked with PBS-T containing 5%
(w/v) dried skimmed milk powder for at least 1 h. The membranes
were washed in PBS-T before incubation with PBS-T containing the pri-
mary antibody (Anti-His (C-term), Life Technologies, CA, USA) for 1 h.
The membranes were washed before incubation with the secondary
antibody (Anti-Mouse IgG (H + L), HRP Conjugate, Promega, WI, USA)
for another hour. The membranes were washed and immunoreactive
bands were detected using an ECL (enhanced chemiluminescence) kit
(BioRad, Herts, UK) according to the manufacturer's instructions. Mem-
branes were developed using a BioRad chemiluminescence imager and
corresponding software. hGH was puriﬁed by expression of TorA-hGH
in 1.2 L wild type cells and puriﬁcation from the periplasmic extracts,
or expression in tatmutant cells and puriﬁcation from the cytoplasmic
fraction. The extractwas subjected to IMAC chromatography in the pres-
ence of 20 mM Tris-HCl, pH 8.6 and the protein was eluted in 50 mM
EDTA. The elute was desalted and subjected to Q-Sepharose chromatog-
raphy in the same buffer, with elution carried out by addition of the
same buffer containing 300 mM NaCl.
2.5. Mass spectrometry: in-gel digestion of proteins
Excised, diced protein bands from Coomassie-stained SDS gels
were washed, reduced and S-alkylated essentially as described in
Fox et al. [8]. A sufﬁcient volume of 2 ng/μL of trypsin (modiﬁed se-
quencing grade, Promega, Southampton, UK) in 25 mM ammonium
bicarbonate was added to cover the gel pieces and digestion per-
formed overnight at 20 °C. The digests were then acidiﬁed by the ad-
dition of a 0.5 volume of 50% acetonitrile with 5% formic acid prior to
MS and MS–MS analysis.
2.6. MS, MS–MS and Electrospray MS analysis
The sample (1 μL of the above peptide digest) was placed on the
sample target (AnchorChip standard, 800 μm) and dried. Subsequent-
ly 0.5 μL of matrix was added and dried. The matrix was α-cyano-4-
hydroxy-cinnamic acid (α-CHCA, 0.7 mg mL−1 in 85% acetonitrile,
15% H2O, 0.1% TFA and 1 mM NH4H2PO4). For external calibration in
the protein mass range, Peptide Calibration Standard I (Bruker)
standards were used. MALDI TOF MS and MALDI TOF–TOF MS–MS
analyses were performed (in the positive ion mode) using a Bruker
UltraﬂeXtreme. The spectra were obtained in reﬂector mode with an
acceleration voltage of 25 kV and a pulse ion extraction time of
80 ns. The mass range for MS was generally between 700 and
3500 m/z. The number of laser shots summed in MS was 3500. The
number of laser shots summed in MS–MS was 3000. The software
ﬂexAnalysis (Bruker, Bremen, Germany) was used for peak picking
prior to using the standard Mascot search engine. The peptide mass
ﬁngerprint was searched against the non-redundant Swiss-Prot pro-
tein database (all organisms) placed in the public domain by UNIProt
and modiﬁed by the addition of sequences corresponding to the
recombinant fusion proteins being studied in this manuscript.
ﬂexAnalysis takes advantage of the isotopic envelope available from
high resolution MS–MS spectra in peptide identiﬁcation. Mascot is
available from Matrix Science Ltd, London, UK.Electrospray LC–MS of intact proteins: Electrospray mass spectra
were recorded on a Bruker micrOTOF-Q II mass spectrometer. Samples
were desalted on-line by reverse-phase HPLC on a Phenomenex Jupiter
C4 column (5 μm, 300 Ǻ, 2.0 mm× 50mm) running on an Agilent 1100
HPLC system at a ﬂow rate of 0.2 mL/min using a short water, acetoni-
trile, 0.05% triﬂuoroacetic acid gradient. The eluant was monitored at
214nmand thendirected into the electrospray source, operating in pos-
itive ion mode, at 4.5 kV and mass spectra recorded from 50–3000 m/z.
Datawere analysed anddeconvoluted to give unchargedproteinmasses
with Bruker's Compass Data Analysis software.
2.7. Site-speciﬁc mutagenesis
hGH mutants were made using the Agilent site-directed mutagene-
sis protocol. The primers used for the C53S mutation were (5′ to 3′):
CCCCCAGACCTCCCTCTCTTTCTCAGAGTCTATTCCGAC and GTCGGAATAG
ACTCTGAGAAAGAGAGGGAGGTCTGGGGG. For the C189S mutant the
following primers were used: GTGGAGGGCAGCTCTGGCTTCCATCATC
ATCATCATCAC and GTGATGATGATGATGATGGAAGCCAGAGCTGCCCTC
CAC. For the double C53S C189S mutant, the C189S mutant was used
as a template with the C53S primers (described previously.
3. Results
3.1. IFN, hGH, an scFv and a VHdomain construct are all efﬁciently exported
by Tat in the absence of prior disulﬁde formation
Previous studies [5,16] showed that several disulﬁde-bonded pro-
teins, including PhoA, a phytase AppA, an scFv construct and a Fab frag-
ment, were exported in E. coliwhen a Tat signal peptide was present at
theN-terminus, provided that disulﬁde formation could occur in the cy-
toplasm. In one case this was achieved by expression in Δgor/ΔtrxB
cells; this strain passively enables the formation of disulﬁde bonds in
proteins in the cytoplasm by the removal of the two naturally occurring
reducing pathways [23]. In the other case the proteins were expressed
in ‘CyDisCo’ strains that express Erv1p and PDI in the cytoplasm, actively
promoting efﬁcient disulﬁde bond formation. The same constructs were
not exported in wild type strains, with the Tat pathway clearly identify-
ing these constructs as ‘inappropriately folded’ and rejecting them.
The primary aimof this studywas to testwhether the Tat system can
export other disulﬁde-bonded therapeutic proteinswith high efﬁciency,
and we chose human growth hormone (hGH), human interferon α2b
(IFN), an scFv raised against the omega peptide of β-galactosidase (de-
scribed in [13]) and an antibody VH domain construct [7] as targets. We
used constructs containing C-terminal His tags to aid identiﬁcation of
the proteins, and all proteins bore N-terminal TorA signal peptides (as
used in [16]) to direct export by the Tat pathway. The precursor proteins
were expressed on a pET23-based plasmid either alone or togetherwith
Erv1p and PDI.
Fig. 1 shows export assays using TorA-hGH and TorA-IFN. After a 3 h
induction of expression, the cells were fractionated to yield cytoplasm,
membrane and periplasm samples (C, M, P) whichwere immunoblotted
using antibodies to the His tags on the target proteins. The ﬁgure shows
thatmost of the TorA-IFN is exported to the periplasm (P) and processed
to themature size (20.7 kDa). A small amount of precursor protein is ap-
parent in the membrane fraction and some mature-size protein is also
present in the cytoplasm. This is commonly found during export of Tat
substrates, probably because the signal peptide is prone to proteolytic
clipping (see e.g. [15]). The export of TorA-hGH is even more efﬁcient;
the vast majority of protein is found in the periplasm and the precursor
form is barely detectable in the cytoplasm.
Fig. 1 also shows similar assays carried out in wild type cells, i.e. in
the absence of Erv1p/PDI. Surprisingly, export of both proteins is again
highly efﬁcient and both proteins are found predominantly in the peri-
plasm asmature size proteins. Next, we tested for the export of the scFv
and VH domain constructs, and export assays in wild type and CyDisCo
Fig. 1. Efﬁcient Tat-dependent export of IFN and hGH by Tat in both the presence and absence of CyDisCo components. hGH and IFNwere expressedwith a TorA Tat signal peptide in E. coli
in the presence or absence of the CyDisCo components Erv1p and PDI. After 3 h, cells were separated into cytoplasm/membrane/periplasm fractions (C, M, P) and samples were
immunoblotted to detect the proteins. Mobilities of mature-size hGH and IFN are indicated, together with a faint TorA-IFN band in the ‘+CyDisCo’ panel. The mobilities of molecular
mass markers are indicated (in kDa) on the left.
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substrates, in that a substantial proportion of the scFv, and themajority
of the VH domain construct, are found in the periplasm in both Erv1p/
PDI-expressing and wild type cells. The TorA-scFv and TorA-VH precur-
sor proteins are detected in the cytoplasm andmembrane fractions, but
a large proportion of scFv and most of the VH domain protein are pres-
ent in the periplasm.
3.2. TorA-scFv is exported exclusively by the Tat pathway
The data shown in Figs. 1 and 2 are surprising because the Tat-
dependent export of other disulﬁde-bonded proteins has shown an ab-
solute dependence on prior cytoplasmic disulﬁde bond formation, as
explained above.We therefore considered it possible that the substrates
tested in this study may in fact be exported by the Sec pathway, since
Sec-type signal peptides are similar in overall structural terms to Tat sig-
nal peptides. To test this possibility directly, we expressed some of the
same constructs in tat null mutant cells and the data for TorA-scFv are
shown in Fig. 3. The results show that the scFv is not exported in the
tatmutant strain to any signiﬁcant extent, either in the absence or pres-
ence of Erv1p/PDI; all of the protein is found in the spheroplast fraction
(Sp). In control assays, export to the periplasm (P) is again observed in
bothwild type and CyDisCo strains, conﬁrming that the export observedFig. 2. scFv and VH domain antibody constructs are exported by Tat in the presence and
absence of CyDisCo components. TorA-scFv and TorA-VH domain constructs were
expressed in wild type or CyDisCo cells as described for IFN and hGH, and cells were frac-
tionated to yield cytoplasm, membrane and periplasm samples (C, M, P). The samples
were analysed by immunoblotting using antibodies to the His tag, and mobilities of
TorA-scFv, mature scFv (‘scFv’), TorA-VH domain protein and mature VH domain protein
are indicated.Mobilities ofmolecularmassmarkers (in kDa) are indicated on the left (scFv
panel) or right (VH domain panel).in Figs. 1 and 2 can be attributed solely to the Tat pathway. Identical re-
sults were obtained for the TorA-IFN and the TorA-VH domain protein
(data not shown). These results are perhaps not surprising; in our pre-
vious study [16] we tested whether a different TorA-signal containing
scFv was exported exclusively via Tat, by substituting the critical twin-
arginine motif in the signal peptide with twin-lysine. The mutation to-
tally blocked transport, conﬁrming that the protein was transported
by the Tat pathway.3.3. TorA-scFv is efﬁciently exported and accurately processed to themature
size
The immunoblots shown in Figs. 1 and 2 show that the four proteins
appear to be exported with high efﬁciency by the Tat pathway, in the
sense that the majority of detected protein is in the periplasm. In
order to assess the actual export ﬂux, and to additionally test whether
the proteins are correctly processed to the mature size, we analysed
the samples by Coomassie staining of the periplasm sample and mass
spectrometry of the exported scFv. Fig. 4A shows a Coomassie-stained
gel of the periplasmic fractions after expression of TorA-scFv in wild
type MC4100 cells or the tat null mutant strain, in either the presence
or absence of Erv1p/PDI. The immunoblot (lower panel) shows that
the scFv protein is present in the periplasm of the wild type cells and
the Coomassie-stained gel (upper panel) shows that this corresponds
to an abundant 28 kDa protein that is absent from the periplasm of
the tatmutant strain. The presumed scFv bandwas excised and subject-
ed to trypsin digestion and MALDI TOF as described in Materials and
methods. This generated the peptide sequences shown in Fig. 4B
which conﬁrm the protein to be the scFv. Importantly, the N-terminal
peptide sequences correspond precisely to the sequences immediately
following the predicted signal peptidase cleavage site, with no evidence
of incorrect processing or large-scale proteolytic clipping. These resultsFig. 3. Export of TorA-scFv occurs exclusively by the Tat pathway. TorA-scFv was
expressed inwild type and tat nullmutant strains for 3 h, in either the presence or absence
of CyDisCo components as indicated. After this period cells were fractionated and sphero-
plast and periplasm (Sp, P) sampleswere analysed by immunoblotting using antibodies to
the C-terminal His tag on the scFv protein. Themobilities of the precursor andmature scFv
forms are indicated.
Fig. 4. TorA-scFv is efﬁciently exported and accurately processed. A: TorA-scFV was expressed in MC4100 cells or the tat null mutant strains in the presence or absence of CyDisCo com-
ponents as indicated. The periplasmic fractionswere run on Coomassie-stained gels and the putative scFv band (present in the periplasm of wild type cells but not tat null mutant cells) is
indicated. Mobilities of molecular mass markers (in kDa) are indicated on the right. Lower panel shows immunoblot of same gel. B: the putative scFv band from the CyDisCo-expressing
sample was excised and subjected to MALDI TOF for peptide mass ﬁngerprinting. The full mature scFv sequence is shown with the peptides identiﬁed by MS in bold and the sequence
identiﬁed byMS/MS in bold and underlined. C: the scFv protein from the cytoplasm was puriﬁed and analysed by Electrospray ionisation mass spectrometry. Two major peaks were ob-
tained: the larger one (ca. 80% of total signal) showed an intact mass of 28,902 Da indicating that cleavage had occurred at the signal peptidase cleavage site (themature protein sequence
is italicised; see diagram). A second mass of 29,143 Da was also observed for a polypeptide in much lower abundance; this reﬂects cleavage after the arginine residue as shown.
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essed to the mature size following export to the periplasm, and the rel-
ative abundance of the exported scFv, after only a 3 h export assay,
shows that the protein is exported at a high rate in both the presence
and absence of Erv1p/PDI.
It is notable in Fig. 4A that a high proportion of the cytoplasmic TorA-
scFv is degraded to a form that co-migrates with authentic periplasmic
mature scFv, and the data in Fig. 1 likewise show the presence of
mature-size IFN in the cytoplasm. We analysed the cytoplasmic scFv
form by mass spectrometry to identify the cleavage site(s) and the re-
sults are shown in Fig. 4C. In fact the masses of the proteins in the ex-
cised band show that the majority of the protein (about 80%) is
indeed mature-size scFv, with a minor (20%) component cleaved after
the last arginine in the signal peptide as shown. In principle, these re-
sults raise the possibility that cleavage is indeed carried out by signal
peptidase; however, this is unlikely because its active site is on the peri-
plasmic face of the plasma membrane and precursor proteins should
not be able to reach this location in tat null mutant cells. Nevertheless,
the frequent appearance of cytoplasmic mature-size protein in assays
for Tat-dependent export raises interesting questions, and we cannot
rule out the possibility that Tat signal peptides are indeed cleaved by
this enzyme even in the absence of translocation. It may also be the
case that other proteases cleave cytoplasmic precursor protein to pep-
tides that are not detected: it is notable in Figs. 1 and 2 that the levels
of TorA-hGH and TorA-IFN in the cytoplasm are extremely low, and
this may not be due only to their export to the periplasm.Fig. 5. Periplasmic hGH is disulﬁde-bonded after Tat-dependent export in wild type or
CyDisCo-expressing cells. A: TorA-hGH was expressed in the presence or absence of
CyDisCo components as indicated (+/−) and the periplasmic fraction was subjected to
SDS-polyacrylamide gel electrophoresis in the presence or absence of reducing agent (2-
mercaptoethanol) as indicated. The mobilities of reduced and oxidised hGH (red, ox) are
indicated, as is a higher band that is possibly a dimer. B: the same TorA-hGH construct
was expressed in a dsbB− strain in the absence of CyDisCo components, and samples of
the periplasm fraction were again run under reducing or non-reducing conditions as in
A. Mobilities of oxidised and reduced hGH forms are indicated (ox, red).3.4. Tat-exported hGH and scFv acquire disulﬁde bonds in the periplasm
The 4 proteins tested in this study are clearly exported by Tat in the
absence of disulﬁde bond formation, andwe next testedwhether one of
the proteins acquires disulﬁde bonds in the periplasm. The DsbABCD
system catalyses disulﬁde bond formation in the periplasm (reviewed
in [12]), usually with proteins that have been exported by the Sec path-
way in an unfolded state. In contrast, the Tat pathway almost certainly
exports proteins in either a fully folded or near-native state, and under
such circumstances it is by no means clear whether the Dsb system
can access the required thiol groups in order to catalyse disulﬁde bond
oxidation. This issue was investigated by analysis of the periplasmic
proteins on reducing vs non-reducing SDS polyacrylamide gels;
disulﬁde-bonded proteins usually migrate differently under non-
reducing conditions because the presence of disulﬁde bonds prevents
full SDS-dependent unfolding of the proteins.Fig. 5A shows immunoblots of periplasmic hGH after export in
Erv1p/PDI — expressing or wild type cells. The samples were run
under reducing or non-reducing conditions (the latter samples were
run in duplicate, in case reducing agent diffused to the adjacent lane).
hGH run under non-reducing conditions clearly migrates faster than
the fully reduced sample, conﬁrming that this protein sample contains
disulﬁde bonds. Importantly, the vast majority of the protein from
both CyDisCo and wild type cells runs with this increased mobility (de-
noted ‘hGH (ox)’), conﬁrming the presence of disulﬁde bonds and pro-
viding strong evidence that hGH exported in wild type cells acquires
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further up the gel, possibly indicating formation of some dimer under
these conditions.
It seemed likely that the exported, reduced hGH would acquire di-
sulﬁde bonds using the DsbABCD machinery that catalyses disulﬁde
bond formation in exported Sec substrates, and this was tested using
the same approaches. TorA-hGH was expressed in a dsbB− strain that
was previously used to study disulﬁde bond formation in other
exported substrates [16] and the data are shown in Fig. 5B. In the ab-
sence of Erv1p/PDI, hGH is exported and the samples migrate as the
usual 19 kDa band under reducing conditions (‘hGH (red)’). Important-
ly, the samples still run primarily with the same mobility under non-
reducing conditions, with only a minority migrating more rapidly like
the oxidised form (hGH (ox)). We interpret these data to indicate
that, in the absence of DsbB, the bulk of the exported hGH is unable to
properly form disulﬁde bonds, strongly suggesting that the DsbABCD
machinery catalyses the formation of the bonds in the experiment
shown in Fig 5B. A minor proportion of exported hGH does appear to
contain disulﬁde bonds, and we speculate that these may form as a
result of spontaneous oxidation.
We also puriﬁed larger amounts of hGH from periplasmic samples
after export in CyDisCo and wild type cells, and analysed the protein
under reducing and non-reducing conditions. Fig. 6 shows that the pu-
riﬁed hGH samples fromCyDisCo andwild type cells both run as the ex-
pected 19 kDa band on reducing gels, whereas the faster-migrating
form (containing disulﬁde bonds) is observed under non-reducing con-
ditions. Importantly, the latter form predominates to an equal extent
after puriﬁcation from either wild type or CyDisCo cells, showing that
the periplasmic protein can become essentially fully folded and
disulﬁde-bonded whether the disulﬁde bonds are formed in the cyto-
plasm or periplasm. Taken together, the data from Figs. 5 and 6 indicate
that the Tat system can export these proteins evenwhen they lack disul-
ﬁde bonds, and that these bonds can form after entry into the periplasm.3.5. The Tat system can transport hGH even when disulﬁde bond formation
is blocked by substitution of the Cys residues involved
The above studies imply that the Tat system is transporting a range
of substrates in a reduced form, possibly because they are able to attain
a near-native structure in the absence of disulﬁde bond formation. This
is an important issue and we considered it important to conﬁrm that a
substrate can deﬁnitely be transported in the absence of prior disulﬁde
bond formation. To do this we used site-speciﬁc mutagenesis to block
disulﬁde bond formation in the hGH substrate. hGH contains two disul-
ﬁde bonds; one between Cys53 and Cys165 (a long-range bond be-
tween residues remote from each other in sequence), and the other
between Cys182 and Cys189 (a short range bond) (Fig. 7). SubstitutionFig. 6. hGH is almost completely disulﬁde-bonded after puriﬁcation from the periplasm of
wild type or CyDisCo-expressing cells. TorA-hGH was expressed in wild type or CyDisCo-
expressing cells and the protein was puriﬁed from periplasmic extracts by IMAC chroma-
tography as detailed in Materials and methods. The protein was run on SDS polyacryl-
amide gels in the presence or absence of 2-mercaptoethanol as indicated. Mobilities of
oxidised and reduced forms are indicated.of Cys53 by serine (variant C53S) prevents formation of the ﬁrst bond
whereas substitution of Cys189 by serine (C189S) blocks formation of
the second. We tested for export of the C53S and C189S single mutants
and the C53S/C189S double mutant, and the data are shown in Fig. 7;
the positions of the above disulﬁde bonds in hGH are also illustrated
in Fig. 7.
The blot shows periplasmic samples from the export assays and the
reduced samples (on the left) show thepresence of very similar levels of
exported periplasmic hGH in each case. None of the substitutions ad-
versely affect translocation-competence. Analyses of the samples
under non-reducing conditions are shown on the right hand side of
the ﬁgure. The wild type protein shows the characteristic increase in
mobility that accompanies disulﬁde bond formation, and the same in-
crease in mobility is observed with the C189S mutant. On the other
hand, the C53S and doublemutant do not show this increase inmobility
and insteadmigratewith the samemobility as the reduced samples.We
conclude that the ﬁrst disulﬁde bond (disrupted in C53S) is solely re-
sponsible for the shift in mobility in SDS polyacrylamide gels whereas
disruption of the second bond (in C189S) does not have a signiﬁcant ef-
fect. This is consistent with the protein structure (Fig. 7). The C182–
C189 disulﬁde bond is a short-range bond whereas the C53S–Cys165
bond is a long range bond that effectively ties together distant regions
of the protein. It is therefore unsurprising that the presence of this
bond has a major effect on protein mobility when the sample is run
under denaturing, non-reducing conditions. Notably, the Tat system ex-
ports all these variants and thus appears to recognise the proteins as
correctly folded, despite the absence of one or both disulﬁde bonds.
4. Discussion
A number of previous reports [5,14,16] have shown that the Tat sys-
tem has an effective, although poorly understood, quality control sys-
tem that enables it to identify and reject proteins that are misfolded.
This feature is important for the normal functioning of the system:
many of its substrates are cofactor-containing proteins and it is impor-
tant that these are only exported in a folded, assembled state. The fea-
ture does not only operate during the export of natural Tat substrates,
however, since this selectivity operates towards a variety of heterolo-
gous proteins when expressed with Tat signal peptides, including
some mammalian disulﬁde-bonded proteins.
The Tat pathway has considerable potential for the industrial pro-
duction of biopharmaceuticals, since it is known to be capable of
exporting a number of ‘Sec-incompatible’ proteins and is furthermore
capable of exporting them at high rates in fermenter systems [15].
Moreover, the inbuilt quality control feature should enable the system
to preferentially export proteins that are correctly folded, which is a po-
tentially valuable trait for biotechnological applications. It was believed
that the export of disulﬁde-bonded proteins would be problematic,
since these cannot form native structures in the cytoplasm, but recent
studies have shown that CyDisCo strains offer potential as a means of
presenting the Tat system with prefolded, disulﬁde-bonded substrates
that it can export to the periplasm [16]. The main aim of the present
study was to determine whether this CyDisCo-Tat combination could
be used for the production of other disulﬁde-bonded proteins, especial-
ly biotherapeutics.
We approached this issue by testing for export of human interferon
α2b, hGH, an scFv and a VH domain construct. We show that all are
exported by the Tat system with high efﬁciency; indeed, the export ef-
ﬁciencies observed with some of these substrates are higher than
those we observe with many native Tat substrates, despite expressing
these heterologous substrates at relatively high levels using pET23-
based plasmids. However, the major surprise from this study is that
none of these substrates require prior disulﬁde bond formation for ex-
port; the proteins are all exported with similar, usually undiminished
efﬁciencies inwild type cellswhere the reducing cytoplasmprevents di-
sulﬁde bond formation prior to export. The likely explanation is that the
Fig. 7. Complete disruption of one or both disulﬁde bonds in hGH does not affect export by the Tat pathway. Ribbon diagram of the hGH structure showing the positions of the disulﬁde
bonds (between C53 and C165, and C182–C189). Site-speciﬁc mutagenesis of TorA-hGH was carried out to substitute one of the Cys residues involved in the ﬁrst or second disulﬁde
bond (Cys53, Cys189, respectively) by serine. A third, double-mutant combined both substitutions. All 3 variants were expressed in E. coliW3110 cells, together with non-mutated
TorA-hGH (WT), and the periplasmic fractions were isolated. These samples were run on SDS-polyacrylamide gels under reducing (left) or non-reducing (right) conditions. Mobilities
of oxidised and reduced hGH are indicated.
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by the Tat system's proofreading system. Indeed, one of the substrates,
hGH, is known to adopt a near-native structure in the absence of disul-
ﬁde bond formation, and is even active in this state [3,30].
These experiments were carried out in a very similar manner to
those described in Matos et al. [16] and the question is why this set of
substrates shows such differing requirements for export. We believe
that the most likely reason relates to the folding complexity of the pro-
teins studied in those previous reports by DeLisa et al. [5] and Matos
et al. [16]. PhoA is a 51 kDa protein with two sequential disulﬁde
bonds, while AppA is a 53 kDa protein with 4 disulﬁde bonds. The
dimeric Fab construct studied in the DeLisa et al. [5] report is particular-
ly complex with both intra-chain and inter-chain disulﬁde bonds. In
contrast, the proteins tested in the present study are smaller, with mo-
lecular masses of 20.7 kDa (IFN), 23.6 kDa (hGH), 28.9 kDa (scFv) and
none contain more than 2 disulﬁde bonds. One possibility is that the
simpler 3-dimensional structure of the proteins enables them to acquire
native, or near-native structures in the absence of disulﬁde bond forma-
tion. However, we would emphasise that this scenario may well be too
simplistic, and in our view it is likely that other factors dictate whether
the Tat-dependent export of such proteins is reliant on prior disulﬁde
formation, and hence on the CyDisCo components Erv1p and PDI.
Finally, the data have implications for the mechanism of the Tat
proofreading system. While this system has a remarkable ability to de-
tectwhether substrates are folded, it is clearly not perfect and the 4 sub-
strates analysed in this study were able to ‘fool’ the translocation
pathway and undergo transport. The ﬁrst point is that the Tat system
clearly cannot detect whether disulﬁde bonds have formed in sub-
strates, at least in these proteins. The second point is that, assuming
that all 4 substrates are not 100% correctly folded in the absenceof disul-
ﬁde bond formation, there appears to be some margin for error in the
proofreading mechanism. It will be interesting to determine just how
close to ‘native’ such Tat substrates' structures need to be, in order to un-
dergo translocation.
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